AU2022200366B2 — Semifluorinated compounds for ophthalmic administration
Assigned to Novaliq GmbH · Expires 2023-11-09 · 3y expired
What this patent protects
The present invention is directed to an ophthalmic composition comprising emifluorinated compounds characterized by the general formula CF3-[CF2]n :H[CH3]-[CH2)m-CH3 wherein n is an integer selected from 3 to 5 and m is an nteger selected from 1 to 5. The invention further prov…
USPTO Abstract
The present invention is directed to an ophthalmic composition comprising emifluorinated compounds characterized by the general formula CF3-[CF2]n :H[CH3]-[CH2)m-CH3 wherein n is an integer selected from 3 to 5 and m is an nteger selected from 1 to 5. The invention further provides the use of the :omposition as medicament for topical administration to the eye, as well as a kit :omprising the composition and a container comprising a dispensing means such is a dropper.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.